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Introduction: Desmoid tumors (also called aggressive fibromatosis) are histologically benign, but have a strong
tendency to recur locally after resection. They are rare neoplastic tumors that may occur sporadically or in
association with familial adenomatous polyposis caused by a germline mutation in the adenomatous polyposis coli
gene. The etiology of desmoid tumors is unknown, but their association with a history of abdominal surgery,
trauma, and estrogen therapy is well known.
Case presentation: A 36-year-old Asian woman was referred complaining of an abdominal tumor. She had no history
of familial adenomatous polyposis, abdominal surgery, trauma or pregnancy. A laparoscopy-assisted right
hemicolectomy with a minilaparotomy was conducted for resection of her right-side colon and the anterior wall of her
duodenum. The histopathological diagnosis was a desmoid tumor that grew from the transverse mesocolon. Mutational
analysis indicated a mutation of the β-catenin gene (CTNNB1), consisting of a substitution of threonine for alanine at
codon 41. The patient has been followed postoperatively for more than 3 years without any sign of recurrence.
Conclusion: We report a case of sporadic colonic desmoid tumor which was resected by laparoscopic surgery. A
successful outcome was achieved because there has been no local recurrence for more than 3 years. The tumor grew
from the transverse mesocolon, and harbored a mutation of the CTNNB1 gene. Mutational analysis of CTNNB1 gene may
play an important role as a prognostic marker of desmoid tumors.
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Desmoid tumors (also called aggressive fibromatosis) are
uncommon mesenchymal neoplasms with a fibrotic band-
like consistency, and are locally aggressive tumors without
the potential for distant metastases [1]. They are histologi-
cally benign, but have a strong tendency to invade locally
and to recur after resection. The incidence of desmoid tu-
mors in the general population is two to four patients per
million per year, with a slight female preponderance and a
peak incidence in the third and fourth decades [2]. The as-
sociation of desmoid tumors with familial adenomatous
polyposis (FAP) is well established [3]. Trauma, prior sur-
gery, pregnancy and estrogen therapy are other risk fac-
tors [4]. Desmoid tumors can develop at any site of the* Correspondence: kkawada@kuhp.kyoto-u.ac.jp
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reproduction in any medium, provided the orbody, but most frequently occur in the extremities of the
trunk, abdominal wall, and within the abdomen. Intra-
abdominal desmoids predominate in patients with FAP,
especially after abdominal surgery and trauma [4].
Case presentation
A 36-year-old Asian woman was admitted to our hospital
with an abdominal mass in the right lower abdomen. The
mass was incidentally found by an ultrasonography. On
physical examination, the mass was firm, painless, about
3cm in diameter, and not fixed to the abdominal wall. She
had no history of abdominal surgery, abdominal injury,
pregnancy or FAP. Results of laboratory blood tests,
including tumor markers, were within normal ranges.
Computed tomography (CT) showed a nodular enhancing
soft-tissue mass that was very close to the transverse colon.
Magnetic resonance imaging (MRI) showed a tumor with
lower signal intensity on T1-weighted imaging and withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 On the positron emission tomography scan, the
heterogeneous uptake (arrows) of 18F-fluorodeoxyglucose was
seen in the middle-lower abdomen, and no definite metastatic
lesion was observed. (a) Coronal plane. (b) Axial plane.
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A positron emission tomography CT scan demonstrated
heterogeneous uptake of 18F-fluorodeoxyglucose into the
tumor, and no definite metastatic lesions (Figure 2).
Laparoscopic surgery was attempted under a presump-
tive diagnosis of gastrointestinal stromal tumor (GIST) or
other soft-tissue tumor of the transverse colon. The tumor
was found to originate from the transverse mesocolon, and
the transverse colon and the anterior wall of the duode-
num were involved (Figure 3). Duodenal involvement was
limited to a small extent. Therefore, in order to resect the
tumor en bloc, laparoscopy-assisted right hemicolectomy
was conducted with a minilaparotomy for partial resection
of the anterior wall of the patient’s duodenum. The ante-
rior wall of her duodenum was closed by a linear stapler.
Finally, we confirmed that the patency of the duodenal
lumen was preserved.
The resected specimen yielded a yellowish white solid
tumor, measuring 40 × 40 × 25mm (Figure 4a). No ne-
crosis was seen. Microscopically, the tumor directly in-
volved the muscularis propria of the transverse colon,
and was very close to the duodenal muscularis propria
(Figure 4b). The surgical margin was confirmed to be
negative for tumor cells. Pathological examination showed
that the tumor was composed of a loose growth of spindle-
shaped cells with abundant collagen fibers; cellular atypia
and neoplastic change were not observed. Immunohisto-
chemical analysis showed that the tumor cells were nega-
tive for c-Kit, CD34, desmin, α-smooth muscle actin, and
S-100, but positive for β-catenin with nuclear accumula-
tion (Figure 4c). Based on these findings, the diagnosis
of colonic desmoid tumor was established. It has been
reported that dysregulation of the Wnt-adenomatous
polyposis coli (APC)-β-catenin signaling cascade plays a
key role in the pathogenesis of sporadic desmoid tumorFigure 1 Magnetic resonance imaging findings showed the desmoid
(a) and high signal intensity on T2-weighted image (b and c). Note th
(a and b) Axial plane. (c) Coronal plane.[3,4]. Therefore, mutational analyses of the β-catenin gene
(CTNNB1) and APC gene were performed, and then a
point mutation of the CTNNB1 gene was found at codon
41 (a substitution of threonine for alanine; Figure 4d). The
patient started oral intake 3 days after the operation, and
then was discharged without any complications 2 weeks
after the operation. No postoperative adjuvant treatment
was done, because she did not want to take it due to her
desire to preserve her fertility. Follow-up CT scans have
been taken every 6 months after the operation. She has
been followed postoperatively for more than 3 years with-
out any signs of recurrence.Discussion
Desmoid tumors are rare neoplastic tumors that may
occur sporadically or in association with FAP caused by
a germline mutation in the APC gene. The etiology oftumor (arrows) with lower signal intensity on T1-weighted image
at the desmoid tumor was next to contrast-filled transverse colon.
Figure 3 Intraoperative findings. Note that the desmoid tumor
seemed to originate from the transverse mesocolon, and it involved
the duodenum and transverse colon.
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a history of abdominal surgery, trauma, and estrogen
therapy (for example oral contraceptive) is well known
[4]. Patients with FAP and a family history of desmoid
tumors have a 25% chance of developing desmoid tu-
mors. With the increasing use of prophylactic colec-
tomy, desmoid tumors have become an important cause
of death in up to 11% of patients with FAP [5]. Intra-
abdominal desmoid tumors account for less than 10% of
sporadic desmoid tumors, and are particularly common
in patients with FAP. The most common groups associ-
ated with sporadic desmoid tumors are young women
during or after pregnancy. The fibroblast has been shown
to exhibit a proliferative response to estrogen. Women
with desmoid tumors experience regression of their le-
sions after attaining menopause [4]. However, in this case,
the patient is nulliparous and has none of the risk factors
mentioned above.
In this case, the tumor was thought to be a GIST before
the operation. The imaging of a desmoid tumor relies
mainly on CT and MRI in practice [3]. Desmoid tumors
have a heterogeneous signal and inhomogeneous enhance-
ment because of the variable distribution of spindle cells,
collagen and myxoid matrix. CT shows a soft-tissue mass
of variable attenuation and enhancement. On T2-weighted
MRI, signal intensity is usually intermediate between skel-
etal muscles and subcutaneous fat. Over time, they become
more hypointense because of increasing collagen depo-
sition and decreasing cellularity. There are no radiographic
characteristics that can reliably distinguish desmoid tumors
from other soft-tissue tumors including GIST. Although
the imaging may be suggestive, histopathological confir-
mation is usually necessary for the correct diagnosis.
Sporadic desmoid tumors harbor somatic mutations
in either the APC gene or CTNNB1 gene, resulting in β-catenin protein stabilization [6]. In particular, mutations
in CTNNB1 gene have been found in around 85% of
sporadic desmoid tumors [7]. Three discrete mutations
in the CTNNB1 gene were identified: 41A (substitution
of threonine for alanine at codon 41), 45F (substitution
of serine for phenylalanine at codon 45), and 45P (sub-
stitution of serine for proline at codon 45). The 41A-
mutation was observed in the present case. Mutations
in CTNNB1 gene have been described in a variety of
epithelial-originating malignancies [8]. It is very unusual
that only three specific mutations have been noted in
desmoid tumors, whereas most other neoplasms exhibit
a variety of CTNNB1 mutations at multiple codons
[9,10]. These findings may indicate that these specific
CTNNB1 mutations are crucial in desmoid development.
It has also been reported that 5-year recurrence-free
survival is significantly poorer in 45F-mutated desmoid
tumors compared with either 41A-mutation or non-
mutated tumors [7]. Multiple studies have demonstrated
significant nuclear β-catenin expression in desmoid tu-
mors as evaluated by immunohistochemistry. Little is
known concerning the utility of β-catenin expression as
a prognostic marker for desmoid tumors or a possible
association between β-catenin expression levels and the
underlying molecular alterations. Gebert et al. reported
that desmoid tumors exhibiting increased nuclear expres-
sion (defined as >20%) had a significantly higher recur-
rence rate than those lacking nuclear β-catenin expression
[11], whereas Lazar et al. reported that decreased nuclear
β-catenin staining intensity was significantly associated
with recurrence [7]. Further investigations are needed in a
prospective way to evaluate the potential causal relation-
ship between CTNNB1 gene mutation, β-catenin expres-
sion, and desmoid recurrence.
Treatment choice is dictated by anatomic consider-
ations. If feasible, surgical resection with a wide margin
is the mainstay of treatment for symptomatic desmoid
tumors. However, recurrence after surgical resection is
common (19% to 77%) [4]. Treatment options for desmoid
tumors include observation, surgical resection, radiotherapy
or systemic therapy. Radiation has been reported to be
comparable to surgery and is also useful as an adjuvant
treatment to reduce the risk of local recurrence [12]. Sys-
temic therapies include cytotoxic agents (for example,
anthracycline), nonsteroidal anti-inflammatory agents (for
example, celecoxib and sulindac), anti-estrogen hormonal
agents (for example, tamoxifen), and molecular targeted
agents (for example, imatinib and sorafenib) [4]. Garbay
et al. recently reported from a retrospective study of 62
patients with recurrent and/or unresectable desmoid tu-
mors that anthracycline-containing regimens are signifi-
cantly related to a higher response rate [13]. Heinrich et al.
reported that imatinib can be an active agent in the treat-
ment of aggressive desmoid tumors, possibly through
Figure 4 Resected desmoid tumor. (a) A gross appearance of the tumor (white arrow) seemed like a sub-mucosal tumor. (b) Hematoxylin and
eosin (H&E, ×40) stain demonstrated that the tumor was directly involved in the muscularis propria of the transverse colon (left), and was very
close to the duodenal muscularis propria (right). The broken line indicates the border between the muscularis propria (*) and the tumor (**).
(c) H&E (×400) stain demonstrated spindle cells proliferation and fibroblast-like cells with bland nuclear morphology (upper left). Immunohistochemical
analysis indicated tumor cells were negative for c-Kit (upper right), α-smooth muscle actin (lower left), but positive for β-catenin with nuclear accumulation
(lower right). (d) Tumor sequence indicated a substitution of GCC (threonine) for ACC (alanine) at codon 41.
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did not receive any adjuvant treatment because she desired
to preserve her fertility. Fortunately, she has not exhibited
any recurrence for more than 3 years. Burke et al. reportedthat the recurrence rate of intra-abdominal desmoid tu-
mors was significantly lower in patients without FAP than
in patients with FAP [15]. In addition, mutational analysis
revealed that 41A-mutation in the CTNNB1 gene had
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sis [7]. Further studies pertaining to clinical practice are
required.
Conclusion
We present a rare case of sporadic colonic desmoid tumor
of the transverse mesocolon in a patient without any his-
tory of FAP, abdominal surgery, trauma, or pregnancy. A
laparoscopy-assisted right hemicolectomy with a minilap-
arotomy was conducted for the resection of the patient’s
right-sided colon and the anterior wall of her duodenum.
Mutational analysis indicated the desmoid tumor har-
bored a mutation of the CTNNB1 gene, consisting of a
substitution of threonine for alanine at codon 41. The pa-
tient has not exhibited any evidence of recurrence for
more than 3 years. Mutational analysis of the CTNNB1
gene may play an important role as a prognostic marker
of desmoid tumors.
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